Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PROCEPT BioRobotics Corporation - Common Stock (NQ:PRCT)

25.64 +1.46 (+6.06%)
Streaming Delayed Price Updated: 10:49 AM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about PROCEPT BioRobotics Corporation - Common Stock

< Previous 1 2 3 4 Next >
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
PROCEPT BioRobotics Stock Hits 52-Week Low - Here's Why ↗
PROCEPT BioRobotics (NASDAQ: PRCT) shares down on Q4 2025 results and updated revenue guidance. Q1 sales expected at $79-82 million. 
Via Benzinga
News headline image
PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20 ↗
Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’. 
Via Stocktwits
Topics Artificial Intelligence
PROCEPT BioRobotics Corp (NASDAQ:PRCT) Plummets 27% After Q4 Earnings Miss and Slashed 2026 Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Where PROCEPT BioRobotics Stands With Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 24, 2025 ↗
 
Via Benzinga
Top movers in Wednesday's after hours session ↗
Via Chartmill
News headline image
After a 60% Slide, One Fund Cuts Exposure to This Healthcare Tech Stock by $12.5 Million ↗
This healthcare technology firm develops robotic surgical systems for minimally invasive urology procedures targeting BPH treatment. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Underrated Robotics Stocks Poised for Huge Gains ↗
Via MarketBeat
News headline image
2 Robotics Stocks Riding the Sensor and Medical Boom ↗
The robotics infrastructure layer is delivering explosive returns. 
Via The Motley Fool
News headline image
4 Analysts Assess PROCEPT BioRobotics: What You Need To Know ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About PROCEPT BioRobotics? ↗
 
Via Benzinga
News headline image
5 Analysts Assess PROCEPT BioRobotics: What You Need To Know ↗
 
Via Benzinga
News headline image
Is Procept BioRobotics Stock a Buy After Investment Company Chicago Capital Scoops Up Nearly 1 Million Shares? ↗
Is Procept BioRobotics Stock a Buy After Investment Company Chicago Capital Scoops Up Nearly 1 Million Shares? 
Via The Motley Fool
News headline image
Beyond The Numbers: 4 Analysts Discuss PROCEPT BioRobotics Stock ↗
 
Via Benzinga
News headline image
Assessing PROCEPT BioRobotics: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Procept (PRCT) Q2 Revenue Jumps 48% ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
PROCEPT BioRobotics (PRCT) Earnings Transcript ↗
Via The Motley Fool
Topics World Trade
News headline image
Looking Into PROCEPT BioRobotics's Recent Short Interest ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 6 Takes On PROCEPT BioRobotics ↗
 
Via Benzinga
News headline image
PROCEPT BioRobotics Corp. (NASDAQ:PRCT) Reports Q2 2025 Revenue Growth but Misses Profitability Targets, Triggering After-Hours Decline ↗
PROCEPT BioRobotics posted strong Q2 2025 revenue growth of 48% YoY but missed profitability estimates, triggering an 8% stock drop. The surgical robotics firm raised full-year guidance but faces... 
Via Chartmill
News headline image
Uncovering Potential: PROCEPT BioRobotics's Earnings Preview ↗
 
Via Benzinga
News headline image
Spruce Point Sees Trouble Ahead For Procept BioRobotics ↗
Spruce Point Capital warns of Procept BioRobotics' overstated market potential and growth claims, citing niche product limitations and valuation risks. 
Via Benzinga
News headline image
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos ↗
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
News headline image
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? ↗
Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%). 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.